{
     "PMID": "28336400",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20171121",
     "LR": "20171128",
     "IS": "1879-0712 (Electronic) 0014-2999 (Linking)",
     "VI": "803",
     "DP": "2017 May 15",
     "TI": "Mechanistic characterization of S 38093, a novel inverse agonist at histamine H3 receptors.",
     "PG": "11-23",
     "LID": "S0014-2999(17)30160-7 [pii] 10.1016/j.ejphar.2017.03.013 [doi]",
     "AB": "Histaminergic H3 inverse agonists, by stimulating central histamine release, represent attractive drug candidates to treat cognitive disorders. The present studies aimed to describe the mechanistic profile of S 38093 a novel H3 receptors inverse agonist. S 38093 displays a moderate affinity for rat, mouse and human H3 receptors (Ki=8.8, 1.44 and 1.2microM, respectively) with no affinity for other histaminergic receptors. In cellular models, the compound was able to antagonize mice H3 receptors (KB=0.65microM) and to suppress cAMP decrease induced by an H3 agonist via human H3 receptors (KB=0.11microM). The antagonism properties of the compound were confirmed by electrophysiological studies on rat hippocampal slices (from 0.1muM). In cells expressing a high H3 density, S 38093 behaved as a moderate inverse agonist at rat and human H3 receptors (EC50=9 and 1.7microM, respectively). S 38093 was rapidly absorbed in mouse and rat (Tmax=0.25-0.5h), slowly in monkey (2h), with a bioavailability ranging from 20% to 60% and t1/2 ranging from 1.5 to 7.4h. The compound was widely distributed with a moderate volume of distribution and low protein binding. The brain distribution of S 38093 was rapid and high. In mice, S 38093 significantly increased ex vivo N-tele-Methylhistamine cerebral levels from 3mg/kg p.o. and antagonized R-alpha-Methylhistamine-induced dipsogenia from 10mg/kg i.p. Taken together, these data suggest that S 38093, a novel H3 inverse agonist, is a good candidate for further in vivo evaluations, in particular in animal models of cognition.",
     "CI": [
          "Copyright (c) 2017 Elsevier B.V. All rights reserved."
     ],
     "FAU": [
          "Sors, Aurore",
          "Panayi, Fany",
          "Bert, Lionel",
          "Favale, Dominique",
          "Nosjean, Olivier",
          "Audinot, Valerie",
          "Arrang, Jean-Michel",
          "Buisson, Bruno",
          "Steidl, Esther",
          "Delbos, Jean-Marie",
          "Huhtala, Tuulia",
          "Kontkanen, Outi",
          "Chollet, Anne-Marie",
          "Casara, Patrick",
          "Lestage, Pierre"
     ],
     "AU": [
          "Sors A",
          "Panayi F",
          "Bert L",
          "Favale D",
          "Nosjean O",
          "Audinot V",
          "Arrang JM",
          "Buisson B",
          "Steidl E",
          "Delbos JM",
          "Huhtala T",
          "Kontkanen O",
          "Chollet AM",
          "Casara P",
          "Lestage P"
     ],
     "AD": "Pole d'Innovation Therapeutique Neuropsychiatrie Servier, Croissy-sur-Seine et Suresnes, France. Electronic address: aurore.sors@servier.com. Pole d'Innovation Therapeutique Neuropsychiatrie Servier, Croissy-sur-Seine et Suresnes, France. Pole d'Innovation Therapeutique Neuropsychiatrie Servier, Croissy-sur-Seine et Suresnes, France. Pole d'Innovation Therapeutique Neuropsychiatrie Servier, Croissy-sur-Seine et Suresnes, France. Pole d'Expertise Recherche et Biopharmacie, Servier, Croissy-sur-Seine et Orleans, France. Pole d'Expertise Recherche et Biopharmacie, Servier, Croissy-sur-Seine et Orleans, France. INSERM U 894, Paris, France. Neuroservice, Aix-en-Provence, France. Neuroservice, Aix-en-Provence, France. Pole d'Expertise Recherche et Biopharmacie, Servier, Croissy-sur-Seine et Orleans, France. Charles River Discovery Research Services, Kuopio, Finland. Charles River Discovery Research Services, Kuopio, Finland. Pole d'Expertise Recherche et Biopharmacie, Servier, Croissy-sur-Seine et Orleans, France. Pole d'Expertise Recherche et Biopharmacie, Servier, Croissy-sur-Seine et Orleans, France. Pole d'Innovation Therapeutique Neuropsychiatrie Servier, Croissy-sur-Seine et Suresnes, France.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article"
     ],
     "DEP": "20170321",
     "PL": "Netherlands",
     "TA": "Eur J Pharmacol",
     "JT": "European journal of pharmacology",
     "JID": "1254354",
     "RN": [
          "0 (Azabicyclo Compounds)",
          "0 (Benzamides)",
          "0 (Histamine Agonists)",
          "0 (Histamine H3 Antagonists)",
          "0 (Receptors, Histamine H3)",
          "0 (S 38093)",
          "27YG812J1I (Arachidonic Acid)",
          "820484N8I3 (Histamine)",
          "E0399OZS9N (Cyclic AMP)"
     ],
     "SB": "IM",
     "MH": [
          "Animals",
          "Arachidonic Acid/secretion",
          "Azabicyclo Compounds/*pharmacology",
          "Benzamides/*pharmacology",
          "Cyclic AMP/metabolism",
          "Dose-Response Relationship, Drug",
          "*Drug Inverse Agonism",
          "Hippocampus/drug effects/metabolism",
          "Histamine/metabolism",
          "Histamine Agonists/metabolism/*pharmacokinetics/pharmacology",
          "Histamine H3 Antagonists/metabolism/*pharmacokinetics/pharmacology",
          "Humans",
          "Male",
          "Mice",
          "Rats",
          "Receptors, Histamine H3/*metabolism"
     ],
     "OTO": [
          "NOTNLM"
     ],
     "OT": [
          "Antagonist",
          "Electrophysiology",
          "Functionality",
          "H3",
          "Inverse agonist",
          "Pharmacokinetics"
     ],
     "EDAT": "2017/03/25 06:00",
     "MHDA": "2017/11/29 06:00",
     "CRDT": [
          "2017/03/25 06:00"
     ],
     "PHST": [
          "2016/11/10 00:00 [received]",
          "2017/03/07 00:00 [revised]",
          "2017/03/10 00:00 [accepted]",
          "2017/03/25 06:00 [pubmed]",
          "2017/11/29 06:00 [medline]",
          "2017/03/25 06:00 [entrez]"
     ],
     "AID": [
          "S0014-2999(17)30160-7 [pii]",
          "10.1016/j.ejphar.2017.03.013 [doi]"
     ],
     "PST": "ppublish",
     "SO": "Eur J Pharmacol. 2017 May 15;803:11-23. doi: 10.1016/j.ejphar.2017.03.013. Epub 2017 Mar 21.",
     "term": "hippocampus"
}